Healthcare provider profile · identity verified

Edward Caballero, MD

Internal Medicine · DANVILLE, IL · NPI 1417311317

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	552	182
Amlodipine Besylate	Amlodipine Besylate	394	110
Gabapentin	Gabapentin	377	103
Lisinopril	Lisinopril	326	101
Losartan Potassium	Losartan Potassium	264	80
Omeprazole	Omeprazole	236	65
Levothyroxine Sodium	Levothyroxine Sodium	225	54
Hydrochlorothiazide	Hydrochlorothiazide	206	69
Albuterol Sulfate Hfa	Albuterol Sulfate	178	51
Metoprolol Tartrate	Metoprolol Tartrate	172	45
Jardiance	Empagliflozin	169	42
Tramadol Hcl	Tramadol Hcl	157	30
Metformin Hcl	Metformin Hcl	146	50
Pantoprazole Sodium	Pantoprazole Sodium	141	51
Carvedilol	Carvedilol	139	41
Tizanidine Hcl	Tizanidine Hcl	136	43
Eliquis	Apixaban	135	37
Simvastatin	Simvastatin	125	32
Metoprolol Succinate	Metoprolol Succinate	122	40
Metformin Hcl Er	Metformin Hcl	117	37
Furosemide	Furosemide	114	36
Tamsulosin Hcl	Tamsulosin Hcl	111	36
Citalopram Hbr	Citalopram Hydrobromide	101	29
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	96	19
Fluticasone Propionate	Fluticasone Propionate	94	38
Ozempic	Semaglutide	83	21
Ezetimibe	Ezetimibe	77	25
Duloxetine Hcl	Duloxetine Hcl	75	30
Trazodone Hcl	Trazodone Hcl	74	21
Clopidogrel	Clopidogrel Bisulfate	71	17
Glipizide Er	Glipizide	67	15
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	64	13
Alendronate Sodium	Alendronate Sodium	63	21
Trulicity	Dulaglutide	62	19
Baclofen	Baclofen	59	20
Pregabalin	Pregabalin	55	12
Allopurinol	Allopurinol	52	17
Clonazepam	Clonazepam	51	suppressed
Pravastatin Sodium	Pravastatin Sodium	48	14
Rybelsus	Semaglutide	48	12
Mounjaro	Tirzepatide	47	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	45	20
Isosorbide Mononitrate Er	Isosorbide Mononitrate	45	13
Rosuvastatin Calcium	Rosuvastatin Calcium	40	11
Spironolactone	Spironolactone	39	16
Warfarin Sodium	Warfarin Sodium	38	suppressed
Naproxen	Naproxen	37	13
Zolpidem Tartrate	Zolpidem Tartrate	37	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	34	12
Lovastatin	Lovastatin	34	suppressed
Clotrimazole	Clotrimazole	33	suppressed
Lorazepam	Lorazepam	33	suppressed
Potassium Chloride	Potassium Chloride	33	11
Alprazolam	Alprazolam	32	suppressed
Incruse Ellipta	Umeclidinium Bromide	32	suppressed
Montelukast Sodium	Montelukast Sodium	32	12
Sertraline Hcl	Sertraline Hcl	32	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	32	suppressed
Atenolol	Atenolol	28	suppressed
Famotidine	Famotidine	28	11
Fluoxetine Hcl	Fluoxetine Hcl	28	suppressed
Xarelto	Rivaroxaban	28	suppressed
Chlorthalidone	Chlorthalidone	27	suppressed
Januvia	Sitagliptin Phosphate	27	suppressed
Buspirone Hcl	Buspirone Hcl	26	suppressed
Ropinirole Hcl	Ropinirole Hcl	26	suppressed
Ventolin Hfa	Albuterol Sulfate	26	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	26	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Topiramate	Topiramate	25	suppressed
Tradjenta	Linagliptin	25	suppressed
Aripiprazole	Aripiprazole	23	suppressed
Doxepin Hcl	Doxepin Hcl	23	suppressed
Ibuprofen	Ibuprofen	23	suppressed
Levetiracetam	Levetiracetam	23	suppressed
Norgestimate-Ethinyl Estradiol	Norgestimate-Ethinyl Estradiol	22	suppressed
Prednisone	Prednisone	22	16
Repatha Sureclick	Evolocumab	22	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	21	20
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Finasteride	Finasteride	21	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	19	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	19	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Cephalexin	Cephalexin	18	suppressed
Diclofenac Sodium	Diclofenac Sodium	18	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Torsemide	Torsemide	17	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Klor-Con M20	Potassium Chloride	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Naloxone Hcl	Naloxone Hcl	15	13
Entresto	Sacubitril/Valsartan	14	suppressed
Nystatin	Nystatin	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	14	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Nitroglycerin	Nitroglycerin	13	11
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Verapamil Er	Verapamil Hcl	12	suppressed
Xifaxan	Rifaximin	12	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error